Over the past 7 years, many clinical studies have demonstrated that SGLT2 inhibitors reduce major cardiovascular events, progressive kidney failure, and kidney and cardiovascular death in individuals with diabetes.1-3 SGLT2 inhibitors act directly, and apparently exclusively, on kidney proximal tubule (PT) cells by decreasing the activity of the apical sodium/glucose cotransporter and thereby inhibiting glucose reabsorption by the kidney—resulting in a reduction of blood glucose levels—and also reducing glucose metabolism by the PT.